Liraglutide biosimilar (Nuobot)

利拉鲁肽生物类似药（诺博特）

Report date: 2022/10/25 16:00:17

Base Information

Drug NameLiraglutide biosimilar (Nuobot)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Nuobot Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Nuobot Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A